Wellcome Sanger Institute

Mosaic Therapeutics has closed its $28 million series A funding round and appointed former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies. The funds will also support […]

A new method of separating cancer cells from non-cancer cells has been developed by researchers at the Wellcome Sanger Institute, in a boost for those working to better understand cancer biology using single-cell mRNA sequencing.  The study, published in Communications Biology, improves on existing methods to identify which cells in a sample are cancerous and […]

Animals with a large difference in lifespan and size end their natural lives with a similar number of genetic changes, researchers have discovered.   The findings come from a study by the Wellcome Sanger Institute which analysed genomes from 16 species of mammal to understand the role genetic changes play in ageing and the development of […]